Neurological disorders – including Parkinson’s – are leading source of disability globally
Author: Almaz OhenePublished: 16 November 2017
Prep: Cook: Serves:
New research published this week in the journal ‘JAMA Neurology’ by Professor Bastiaan Bloem, from Radboud University Nijmegen Medical Centre in the Netherlands, and Dr Ray Dorsey from University of Rochester Medical Center, shows that neurological disorders are now the leading source of disability worldwide
The medical community must mobilise to respond to the predicted rapid increase in people living with Parkinson’s over the next twenty years, argue leading Parkinson’s specialists Professor Bastiaan Bloem and Dr Ray Dorsey in a journal article this week.
In an article called ‘Parkinson Pandemic – A Call to Action’ in the journal ‘JAMA Neurology’ earlier this week, the expert physicians point out that between 1990 and 2015, the prevalence of Parkinson’s more than doubled, with an estimated 6.9 million people worldwide living with the condition. They also estimate that by 2040, the number of people with Parkinson’s will increase to 14.2 million as the population ages.
In a bid to combat this growing pandemic, the authors argue that the medical community should pursue the same strategies that transformed HIV from an unknown and fatal illness, into a highly treatable chronic condition.
Dr Ray Dorsey, from the University of Rochester Medical Center, US, said: “Pandemics are usually equated with infectious diseases like Zika, influenza, and HIV – but neurological disorders are now the leading cause of disability in the world and the fastest growing is Parkinson’s disease.”
Their article echoes another study, the ‘Global Burden of Disease’, also co-authored by Dorsey, which appeared in ‘The Lancet Neurology’ in September. That study tracked the prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, stroke, epilepsy, meningitis, encephalitis, multiple sclerosis, and migraine, both globally and by individual country.
Professor Bastiaan Bloem, of the Radboud University NijmegenMedical Centre, the Netherlands, said: “People with HIV infection simply demanded better treatments and successfully rallied for both awareness and new treatments, literally chaining themselves to the doors of pharmaceutical companies. Today, HIV has become a treatable, chronic disease. This upcoming increase in the number of Parkinson’s patients is striking, and frankly, worrisome. We feel it is urgent that people with Parkinson’s go to the pharmaceutical industry and policymakers alike, demanding immediate action to fight this enormous threat.”
Dr Dorsey continued: “For too long Parkinson’s community has been too quiet on these issues. Building on the AIDS community’s motto of ‘silence equals death’, Parkinson’s community should make their voices heard. The current and future burden of this debilitating disease depends upon their action.”
The two academics argue that access to care for Parkinson’s – a highly treatable condition – is also limited. In the US for example, more than 40% of individuals with Parkinson’s over the age of 65 do not see a neurologist, while an online survey of 35 European countries showed that 40% of respondents had never seen a Parkinson’s specialist. In less wealthy nations, many are never diagnosed. In a door-to-door study in Bolivia, none of the individuals found to have the condition had ever been diagnosed or received treatment.
Todd Sherer, CEO of The Michael J Fox Foundation, said: “Too many people have Parkinson’s today and more will face diagnoses tomorrow. We all – government, patient organisations, researchers, doctors and patients – must work together for better care for those living with this disease and research toward a future without Parkinson’s.”
Dr Ray Dorsey Dr Ray Dorsey is David M Levy professor of neurology and director of the Center for Health and Technology at the University of Rochester Medical Center, US, where he is helping investigate new treatments for movement disorders and improve the way care is delivered for people with Parkinson and other neurological disorders.
Dr Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins, Maryland, US. Dr Dorsey’s research has been published in the leading medical, neurology, and economic journals and has been featured in The New York Times, and The Wall Street Journal.
Image credit: University of Rochester Medical Center
Professor Bastiaan Bloem Baastian Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. In 1994, he obtained his PhD degree at the Leiden University Medical Centre, the Netherlands. In 2002, he founded and became medical director of Parkinson Centre Nijmegen (ParC), the Netherlands, which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease.
Together with Dr Marten Munneke, he also developed ParkinsonNet, where people with Parkinson’s “co-design” their treatment programme in collaboration with a dedicated, multi-disciplinary team – accessed via ParkinsonNet’s online database of expert practitioners.
“What we have discovered is the tip of the iceberg”
A new method for early Parkinson’s disease diagnosis?
5 months ago
35 new Parkinson’s drug trials launched in last year
Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.